nodes	percent_of_prediction	percent_of_DWPC	metapath
Imatinib—ALB—Acitretin—psoriasis	0.037	0.0636	CbGbCtD
Imatinib—CYP3A5—Beclomethasone—psoriasis	0.035	0.0602	CbGbCtD
Imatinib—CYP1A2—Clobetasol propionate—psoriasis	0.0344	0.0591	CbGbCtD
Imatinib—ABCG2—Mycophenolate mofetil—psoriasis	0.0251	0.0432	CbGbCtD
Imatinib—ABCG2—Hydrocortisone—psoriasis	0.0202	0.0347	CbGbCtD
Imatinib—ABCG2—Cyclosporine—psoriasis	0.0191	0.0328	CbGbCtD
Imatinib—CYP1A2—Methoxsalen—psoriasis	0.0181	0.031	CbGbCtD
Imatinib—ALB—Mycophenolate mofetil—psoriasis	0.0173	0.0298	CbGbCtD
Imatinib—CYP2D6—Hydroxyurea—psoriasis	0.0163	0.028	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Hydrocortisone—psoriasis	0.0149	0.0256	CbGbCtD
Imatinib—CYP3A7—Hydrocortisone—psoriasis	0.0149	0.0256	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Cyclosporine—psoriasis	0.0141	0.0242	CbGbCtD
Imatinib—CYP3A7—Cyclosporine—psoriasis	0.0141	0.0242	CbGbCtD
Imatinib—CYP3A5—Mycophenolate mofetil—psoriasis	0.0139	0.0239	CbGbCtD
Imatinib—ALB—Prednisone—psoriasis	0.0139	0.0238	CbGbCtD
Imatinib—CYP2C19—Cholecalciferol—psoriasis	0.013	0.0223	CbGbCtD
Imatinib—ABCG2—Dexamethasone—psoriasis	0.0125	0.0216	CbGbCtD
Imatinib—CYP3A4—Calcitriol—psoriasis	0.0122	0.0209	CbGbCtD
Imatinib—CYP3A5—Hydrocortisone—psoriasis	0.0112	0.0192	CbGbCtD
Imatinib—CYP2C9—Cholecalciferol—psoriasis	0.0108	0.0185	CbGbCtD
Imatinib—CYP3A5—Cyclosporine—psoriasis	0.0106	0.0181	CbGbCtD
Imatinib—ABCG2—Methotrexate—psoriasis	0.0101	0.0173	CbGbCtD
Imatinib—CYP2D6—Cholecalciferol—psoriasis	0.00985	0.0169	CbGbCtD
Imatinib—CYP3A4—Methoxsalen—psoriasis	0.00946	0.0163	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Dexamethasone—psoriasis	0.00927	0.0159	CbGbCtD
Imatinib—CYP3A7—Dexamethasone—psoriasis	0.00927	0.0159	CbGbCtD
Imatinib—ABCB1—Mycophenolate mofetil—psoriasis	0.00907	0.0156	CbGbCtD
Imatinib—CYP2C19—Prednisone—psoriasis	0.00898	0.0154	CbGbCtD
Imatinib—CYP2C19—Cyclosporine—psoriasis	0.00852	0.0146	CbGbCtD
Imatinib—ABCB1—Betamethasone—psoriasis	0.00778	0.0134	CbGbCtD
Imatinib—ABCB1—Prednisolone—psoriasis	0.00767	0.0132	CbGbCtD
Imatinib—ABCB1—Hydrocortisone—psoriasis	0.00728	0.0125	CbGbCtD
Imatinib—ABCB1—Prednisone—psoriasis	0.00725	0.0125	CbGbCtD
Imatinib—CYP2C9—Cyclosporine—psoriasis	0.00708	0.0122	CbGbCtD
Imatinib—CYP3A5—Dexamethasone—psoriasis	0.00695	0.012	CbGbCtD
Imatinib—ALB—Methotrexate—psoriasis	0.00695	0.0119	CbGbCtD
Imatinib—ABCB1—Cyclosporine—psoriasis	0.00687	0.0118	CbGbCtD
Imatinib—CYP2D6—Cyclosporine—psoriasis	0.00647	0.0111	CbGbCtD
Imatinib—CYP3A4—Cholecalciferol—psoriasis	0.00626	0.0108	CbGbCtD
Imatinib—CYP2C19—Dexamethasone—psoriasis	0.00561	0.00964	CbGbCtD
Imatinib—CYP3A4—Mycophenolate mofetil—psoriasis	0.00543	0.00934	CbGbCtD
Imatinib—CYP3A4—Triamcinolone—psoriasis	0.00543	0.00934	CbGbCtD
Imatinib—CYP2C9—Dexamethasone—psoriasis	0.00466	0.00801	CbGbCtD
Imatinib—CYP3A4—Betamethasone—psoriasis	0.00466	0.00801	CbGbCtD
Imatinib—CYP3A4—Prednisolone—psoriasis	0.0046	0.0079	CbGbCtD
Imatinib—ABCB1—Dexamethasone—psoriasis	0.00452	0.00778	CbGbCtD
Imatinib—CYP3A4—Hydrocortisone—psoriasis	0.00436	0.00749	CbGbCtD
Imatinib—CYP3A4—Prednisone—psoriasis	0.00434	0.00747	CbGbCtD
Imatinib—CYP2D6—Dexamethasone—psoriasis	0.00426	0.00733	CbGbCtD
Imatinib—CYP3A4—Cyclosporine—psoriasis	0.00412	0.00708	CbGbCtD
Imatinib—ABCB1—Methotrexate—psoriasis	0.00364	0.00625	CbGbCtD
Imatinib—CYP3A4—Dexamethasone—psoriasis	0.00271	0.00466	CbGbCtD
Imatinib—ORM1—vertebral column—psoriasis	0.00226	0.147	CbGeAlD
Imatinib—KIT—skin epidermis—psoriasis	0.00152	0.0984	CbGeAlD
Imatinib—KIT—endothelium—psoriasis	0.0011	0.0714	CbGeAlD
Imatinib—ABCA3—tendon—psoriasis	0.00107	0.0696	CbGeAlD
Imatinib—DDR1—tendon—psoriasis	0.000989	0.0642	CbGeAlD
Imatinib—ABL2—tendon—psoriasis	0.000645	0.0419	CbGeAlD
Imatinib—PIP4K2C—tendon—psoriasis	0.00061	0.0396	CbGeAlD
Imatinib—CA3—tendon—psoriasis	0.000583	0.0378	CbGeAlD
Imatinib—CA9—tendon—psoriasis	0.000558	0.0362	CbGeAlD
Imatinib—CA14—tendon—psoriasis	0.000529	0.0344	CbGeAlD
Imatinib—CSF1R—skin of body—psoriasis	0.000517	0.0336	CbGeAlD
Imatinib—PTGS1—endothelium—psoriasis	0.000504	0.0327	CbGeAlD
Imatinib—KIT—skin of body—psoriasis	0.00047	0.0305	CbGeAlD
Imatinib—PDGFRB—skin of body—psoriasis	0.000459	0.0298	CbGeAlD
Imatinib—NQO2—tendon—psoriasis	0.000448	0.0291	CbGeAlD
Imatinib—PDGFRA—tendon—psoriasis	0.000447	0.029	CbGeAlD
Imatinib—ABL1—skin of body—psoriasis	0.000409	0.0265	CbGeAlD
Imatinib—CSF1R—tendon—psoriasis	0.000394	0.0256	CbGeAlD
Imatinib—SLC47A1—tendon—psoriasis	0.00036	0.0233	CbGeAlD
Imatinib—PDGFRB—tendon—psoriasis	0.000349	0.0227	CbGeAlD
Imatinib—ABL1—tendon—psoriasis	0.000311	0.0202	CbGeAlD
Imatinib—CA2—skin of body—psoriasis	0.000278	0.0181	CbGeAlD
Imatinib—PTGS1—skin of body—psoriasis	0.000215	0.014	CbGeAlD
Imatinib—CA2—tendon—psoriasis	0.000212	0.0138	CbGeAlD
Imatinib—PTGS1—tendon—psoriasis	0.000164	0.0106	CbGeAlD
Imatinib—Rash—Mycophenolic acid—psoriasis	5.12e-05	0.00017	CcSEcCtD
Imatinib—Dermatitis—Mycophenolic acid—psoriasis	5.12e-05	0.00017	CcSEcCtD
Imatinib—Pain—Prednisolone—psoriasis	5.12e-05	0.00017	CcSEcCtD
Imatinib—Haemorrhage—Methotrexate—psoriasis	5.11e-05	0.000169	CcSEcCtD
Imatinib—Hepatitis—Methotrexate—psoriasis	5.11e-05	0.000169	CcSEcCtD
Imatinib—Urticaria—Mycophenolate mofetil—psoriasis	5.1e-05	0.000169	CcSEcCtD
Imatinib—Headache—Mycophenolic acid—psoriasis	5.09e-05	0.000169	CcSEcCtD
Imatinib—Decreased appetite—Hydrocortisone—psoriasis	5.08e-05	0.000168	CcSEcCtD
Imatinib—Pharyngitis—Methotrexate—psoriasis	5.08e-05	0.000168	CcSEcCtD
Imatinib—Abdominal pain—Mycophenolate mofetil—psoriasis	5.07e-05	0.000168	CcSEcCtD
Imatinib—Body temperature increased—Mycophenolate mofetil—psoriasis	5.07e-05	0.000168	CcSEcCtD
Imatinib—Urinary tract disorder—Methotrexate—psoriasis	5.05e-05	0.000167	CcSEcCtD
Imatinib—Gastrointestinal disorder—Hydrocortisone—psoriasis	5.05e-05	0.000167	CcSEcCtD
Imatinib—Fatigue—Hydrocortisone—psoriasis	5.04e-05	0.000167	CcSEcCtD
Imatinib—Vision blurred—Prednisone—psoriasis	5.02e-05	0.000166	CcSEcCtD
Imatinib—Urethral disorder—Methotrexate—psoriasis	5.01e-05	0.000166	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Triamcinolone—psoriasis	5.01e-05	0.000166	CcSEcCtD
Imatinib—Pain—Hydrocortisone—psoriasis	5e-05	0.000166	CcSEcCtD
Imatinib—Oedema—Dexamethasone—psoriasis	4.99e-05	0.000165	CcSEcCtD
Imatinib—Anaphylactic shock—Betamethasone—psoriasis	4.99e-05	0.000165	CcSEcCtD
Imatinib—Anaphylactic shock—Dexamethasone—psoriasis	4.99e-05	0.000165	CcSEcCtD
Imatinib—Oedema—Betamethasone—psoriasis	4.99e-05	0.000165	CcSEcCtD
Imatinib—Insomnia—Triamcinolone—psoriasis	4.98e-05	0.000165	CcSEcCtD
Imatinib—Infection—Betamethasone—psoriasis	4.96e-05	0.000164	CcSEcCtD
Imatinib—Infection—Dexamethasone—psoriasis	4.96e-05	0.000164	CcSEcCtD
Imatinib—Ill-defined disorder—Prednisone—psoriasis	4.94e-05	0.000164	CcSEcCtD
Imatinib—Paraesthesia—Triamcinolone—psoriasis	4.94e-05	0.000164	CcSEcCtD
Imatinib—Feeling abnormal—Prednisolone—psoriasis	4.93e-05	0.000163	CcSEcCtD
Imatinib—Anaemia—Prednisone—psoriasis	4.92e-05	0.000163	CcSEcCtD
Imatinib—Shock—Dexamethasone—psoriasis	4.91e-05	0.000163	CcSEcCtD
Imatinib—Shock—Betamethasone—psoriasis	4.91e-05	0.000163	CcSEcCtD
Imatinib—Dyspnoea—Triamcinolone—psoriasis	4.91e-05	0.000163	CcSEcCtD
Imatinib—Nervous system disorder—Dexamethasone—psoriasis	4.9e-05	0.000162	CcSEcCtD
Imatinib—Nervous system disorder—Betamethasone—psoriasis	4.9e-05	0.000162	CcSEcCtD
Imatinib—Thrombocytopenia—Betamethasone—psoriasis	4.89e-05	0.000162	CcSEcCtD
Imatinib—Thrombocytopenia—Dexamethasone—psoriasis	4.89e-05	0.000162	CcSEcCtD
Imatinib—Tachycardia—Betamethasone—psoriasis	4.87e-05	0.000161	CcSEcCtD
Imatinib—Tachycardia—Dexamethasone—psoriasis	4.87e-05	0.000161	CcSEcCtD
Imatinib—Angioedema—Prednisone—psoriasis	4.87e-05	0.000161	CcSEcCtD
Imatinib—Hypersensitivity—Cyclosporine—psoriasis	4.84e-05	0.00016	CcSEcCtD
Imatinib—Dyspepsia—Triamcinolone—psoriasis	4.84e-05	0.00016	CcSEcCtD
Imatinib—Erythema multiforme—Methotrexate—psoriasis	4.84e-05	0.00016	CcSEcCtD
Imatinib—Nausea—Mycophenolic acid—psoriasis	4.83e-05	0.00016	CcSEcCtD
Imatinib—Hyperhidrosis—Betamethasone—psoriasis	4.83e-05	0.00016	CcSEcCtD
Imatinib—Hyperhidrosis—Dexamethasone—psoriasis	4.83e-05	0.00016	CcSEcCtD
Imatinib—Feeling abnormal—Hydrocortisone—psoriasis	4.82e-05	0.00016	CcSEcCtD
Imatinib—Malaise—Prednisone—psoriasis	4.8e-05	0.000159	CcSEcCtD
Imatinib—Vertigo—Prednisone—psoriasis	4.79e-05	0.000159	CcSEcCtD
Imatinib—Eye disorder—Methotrexate—psoriasis	4.78e-05	0.000158	CcSEcCtD
Imatinib—Gastrointestinal pain—Hydrocortisone—psoriasis	4.78e-05	0.000158	CcSEcCtD
Imatinib—Syncope—Prednisone—psoriasis	4.78e-05	0.000158	CcSEcCtD
Imatinib—Tinnitus—Methotrexate—psoriasis	4.77e-05	0.000158	CcSEcCtD
Imatinib—Anorexia—Dexamethasone—psoriasis	4.76e-05	0.000158	CcSEcCtD
Imatinib—Anorexia—Betamethasone—psoriasis	4.76e-05	0.000158	CcSEcCtD
Imatinib—Urticaria—Prednisolone—psoriasis	4.75e-05	0.000157	CcSEcCtD
Imatinib—Cardiac disorder—Methotrexate—psoriasis	4.75e-05	0.000157	CcSEcCtD
Imatinib—Fatigue—Triamcinolone—psoriasis	4.74e-05	0.000157	CcSEcCtD
Imatinib—Hypersensitivity—Mycophenolate mofetil—psoriasis	4.73e-05	0.000157	CcSEcCtD
Imatinib—Asthenia—Cyclosporine—psoriasis	4.72e-05	0.000156	CcSEcCtD
Imatinib—Pain—Triamcinolone—psoriasis	4.71e-05	0.000156	CcSEcCtD
Imatinib—Loss of consciousness—Prednisone—psoriasis	4.68e-05	0.000155	CcSEcCtD
Imatinib—Hypotension—Dexamethasone—psoriasis	4.67e-05	0.000155	CcSEcCtD
Imatinib—Hypotension—Betamethasone—psoriasis	4.67e-05	0.000155	CcSEcCtD
Imatinib—Pruritus—Cyclosporine—psoriasis	4.65e-05	0.000154	CcSEcCtD
Imatinib—Urticaria—Hydrocortisone—psoriasis	4.64e-05	0.000154	CcSEcCtD
Imatinib—Angiopathy—Methotrexate—psoriasis	4.64e-05	0.000154	CcSEcCtD
Imatinib—Immune system disorder—Methotrexate—psoriasis	4.62e-05	0.000153	CcSEcCtD
Imatinib—Abdominal pain—Hydrocortisone—psoriasis	4.62e-05	0.000153	CcSEcCtD
Imatinib—Body temperature increased—Hydrocortisone—psoriasis	4.62e-05	0.000153	CcSEcCtD
Imatinib—Convulsion—Prednisone—psoriasis	4.62e-05	0.000153	CcSEcCtD
Imatinib—Mediastinal disorder—Methotrexate—psoriasis	4.61e-05	0.000153	CcSEcCtD
Imatinib—Asthenia—Mycophenolate mofetil—psoriasis	4.6e-05	0.000152	CcSEcCtD
Imatinib—Hypertension—Prednisone—psoriasis	4.6e-05	0.000152	CcSEcCtD
Imatinib—Chills—Methotrexate—psoriasis	4.59e-05	0.000152	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Dexamethasone—psoriasis	4.55e-05	0.000151	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Betamethasone—psoriasis	4.55e-05	0.000151	CcSEcCtD
Imatinib—Pruritus—Mycophenolate mofetil—psoriasis	4.54e-05	0.00015	CcSEcCtD
Imatinib—Myalgia—Prednisone—psoriasis	4.54e-05	0.00015	CcSEcCtD
Imatinib—Arthralgia—Prednisone—psoriasis	4.54e-05	0.00015	CcSEcCtD
Imatinib—Feeling abnormal—Triamcinolone—psoriasis	4.53e-05	0.00015	CcSEcCtD
Imatinib—Anxiety—Prednisone—psoriasis	4.52e-05	0.00015	CcSEcCtD
Imatinib—Alopecia—Methotrexate—psoriasis	4.52e-05	0.00015	CcSEcCtD
Imatinib—Insomnia—Dexamethasone—psoriasis	4.52e-05	0.00015	CcSEcCtD
Imatinib—Insomnia—Betamethasone—psoriasis	4.52e-05	0.00015	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	4.5e-05	0.000149	CcSEcCtD
Imatinib—Diarrhoea—Cyclosporine—psoriasis	4.5e-05	0.000149	CcSEcCtD
Imatinib—Paraesthesia—Betamethasone—psoriasis	4.48e-05	0.000149	CcSEcCtD
Imatinib—Paraesthesia—Dexamethasone—psoriasis	4.48e-05	0.000149	CcSEcCtD
Imatinib—Discomfort—Prednisone—psoriasis	4.48e-05	0.000148	CcSEcCtD
Imatinib—Mental disorder—Methotrexate—psoriasis	4.48e-05	0.000148	CcSEcCtD
Imatinib—Erythema—Methotrexate—psoriasis	4.45e-05	0.000147	CcSEcCtD
Imatinib—Malnutrition—Methotrexate—psoriasis	4.45e-05	0.000147	CcSEcCtD
Imatinib—Hypersensitivity—Prednisolone—psoriasis	4.41e-05	0.000146	CcSEcCtD
Imatinib—Dyspepsia—Dexamethasone—psoriasis	4.39e-05	0.000146	CcSEcCtD
Imatinib—Dyspepsia—Betamethasone—psoriasis	4.39e-05	0.000146	CcSEcCtD
Imatinib—Diarrhoea—Mycophenolate mofetil—psoriasis	4.39e-05	0.000145	CcSEcCtD
Imatinib—Urticaria—Triamcinolone—psoriasis	4.37e-05	0.000145	CcSEcCtD
Imatinib—Dysgeusia—Methotrexate—psoriasis	4.36e-05	0.000144	CcSEcCtD
Imatinib—Body temperature increased—Triamcinolone—psoriasis	4.35e-05	0.000144	CcSEcCtD
Imatinib—Dizziness—Cyclosporine—psoriasis	4.35e-05	0.000144	CcSEcCtD
Imatinib—Anaphylactic shock—Prednisone—psoriasis	4.35e-05	0.000144	CcSEcCtD
Imatinib—Oedema—Prednisone—psoriasis	4.35e-05	0.000144	CcSEcCtD
Imatinib—Decreased appetite—Dexamethasone—psoriasis	4.34e-05	0.000144	CcSEcCtD
Imatinib—Decreased appetite—Betamethasone—psoriasis	4.34e-05	0.000144	CcSEcCtD
Imatinib—Infection—Prednisone—psoriasis	4.32e-05	0.000143	CcSEcCtD
Imatinib—Gastrointestinal disorder—Betamethasone—psoriasis	4.31e-05	0.000143	CcSEcCtD
Imatinib—Gastrointestinal disorder—Dexamethasone—psoriasis	4.31e-05	0.000143	CcSEcCtD
Imatinib—Back pain—Methotrexate—psoriasis	4.31e-05	0.000143	CcSEcCtD
Imatinib—Hypersensitivity—Hydrocortisone—psoriasis	4.31e-05	0.000143	CcSEcCtD
Imatinib—Fatigue—Dexamethasone—psoriasis	4.3e-05	0.000143	CcSEcCtD
Imatinib—Fatigue—Betamethasone—psoriasis	4.3e-05	0.000143	CcSEcCtD
Imatinib—Shock—Prednisone—psoriasis	4.28e-05	0.000142	CcSEcCtD
Imatinib—Pain—Dexamethasone—psoriasis	4.27e-05	0.000141	CcSEcCtD
Imatinib—Pain—Betamethasone—psoriasis	4.27e-05	0.000141	CcSEcCtD
Imatinib—Nervous system disorder—Prednisone—psoriasis	4.26e-05	0.000141	CcSEcCtD
Imatinib—Tachycardia—Prednisone—psoriasis	4.24e-05	0.000141	CcSEcCtD
Imatinib—Dizziness—Mycophenolate mofetil—psoriasis	4.24e-05	0.000141	CcSEcCtD
Imatinib—Skin disorder—Prednisone—psoriasis	4.22e-05	0.00014	CcSEcCtD
Imatinib—Hyperhidrosis—Prednisone—psoriasis	4.2e-05	0.000139	CcSEcCtD
Imatinib—Vision blurred—Methotrexate—psoriasis	4.2e-05	0.000139	CcSEcCtD
Imatinib—Asthenia—Hydrocortisone—psoriasis	4.19e-05	0.000139	CcSEcCtD
Imatinib—Vomiting—Cyclosporine—psoriasis	4.18e-05	0.000139	CcSEcCtD
Imatinib—Rash—Cyclosporine—psoriasis	4.15e-05	0.000137	CcSEcCtD
Imatinib—Anorexia—Prednisone—psoriasis	4.14e-05	0.000137	CcSEcCtD
Imatinib—Dermatitis—Cyclosporine—psoriasis	4.14e-05	0.000137	CcSEcCtD
Imatinib—Pruritus—Hydrocortisone—psoriasis	4.13e-05	0.000137	CcSEcCtD
Imatinib—Ill-defined disorder—Methotrexate—psoriasis	4.13e-05	0.000137	CcSEcCtD
Imatinib—Headache—Cyclosporine—psoriasis	4.12e-05	0.000136	CcSEcCtD
Imatinib—Anaemia—Methotrexate—psoriasis	4.12e-05	0.000136	CcSEcCtD
Imatinib—Feeling abnormal—Betamethasone—psoriasis	4.11e-05	0.000136	CcSEcCtD
Imatinib—Feeling abnormal—Dexamethasone—psoriasis	4.11e-05	0.000136	CcSEcCtD
Imatinib—Gastrointestinal pain—Dexamethasone—psoriasis	4.08e-05	0.000135	CcSEcCtD
Imatinib—Gastrointestinal pain—Betamethasone—psoriasis	4.08e-05	0.000135	CcSEcCtD
Imatinib—Vomiting—Mycophenolate mofetil—psoriasis	4.08e-05	0.000135	CcSEcCtD
Imatinib—Hypersensitivity—Triamcinolone—psoriasis	4.05e-05	0.000134	CcSEcCtD
Imatinib—Rash—Mycophenolate mofetil—psoriasis	4.04e-05	0.000134	CcSEcCtD
Imatinib—Dermatitis—Mycophenolate mofetil—psoriasis	4.04e-05	0.000134	CcSEcCtD
Imatinib—Headache—Mycophenolate mofetil—psoriasis	4.02e-05	0.000133	CcSEcCtD
Imatinib—Malaise—Methotrexate—psoriasis	4.02e-05	0.000133	CcSEcCtD
Imatinib—Vertigo—Methotrexate—psoriasis	4e-05	0.000133	CcSEcCtD
Imatinib—Diarrhoea—Hydrocortisone—psoriasis	4e-05	0.000132	CcSEcCtD
Imatinib—Leukopenia—Methotrexate—psoriasis	3.99e-05	0.000132	CcSEcCtD
Imatinib—Urticaria—Betamethasone—psoriasis	3.97e-05	0.000131	CcSEcCtD
Imatinib—Urticaria—Dexamethasone—psoriasis	3.97e-05	0.000131	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Prednisone—psoriasis	3.96e-05	0.000131	CcSEcCtD
Imatinib—Dizziness—Prednisolone—psoriasis	3.96e-05	0.000131	CcSEcCtD
Imatinib—Asthenia—Triamcinolone—psoriasis	3.95e-05	0.000131	CcSEcCtD
Imatinib—Abdominal pain—Betamethasone—psoriasis	3.95e-05	0.000131	CcSEcCtD
Imatinib—Abdominal pain—Dexamethasone—psoriasis	3.95e-05	0.000131	CcSEcCtD
Imatinib—Body temperature increased—Dexamethasone—psoriasis	3.95e-05	0.000131	CcSEcCtD
Imatinib—Body temperature increased—Betamethasone—psoriasis	3.95e-05	0.000131	CcSEcCtD
Imatinib—Insomnia—Prednisone—psoriasis	3.93e-05	0.00013	CcSEcCtD
Imatinib—Nausea—Cyclosporine—psoriasis	3.91e-05	0.000129	CcSEcCtD
Imatinib—Paraesthesia—Prednisone—psoriasis	3.9e-05	0.000129	CcSEcCtD
Imatinib—Pruritus—Triamcinolone—psoriasis	3.89e-05	0.000129	CcSEcCtD
Imatinib—Cough—Methotrexate—psoriasis	3.89e-05	0.000129	CcSEcCtD
Imatinib—Dizziness—Hydrocortisone—psoriasis	3.86e-05	0.000128	CcSEcCtD
Imatinib—Convulsion—Methotrexate—psoriasis	3.86e-05	0.000128	CcSEcCtD
Imatinib—Dyspepsia—Prednisone—psoriasis	3.83e-05	0.000127	CcSEcCtD
Imatinib—Nausea—Mycophenolate mofetil—psoriasis	3.81e-05	0.000126	CcSEcCtD
Imatinib—Arthralgia—Methotrexate—psoriasis	3.79e-05	0.000126	CcSEcCtD
Imatinib—Chest pain—Methotrexate—psoriasis	3.79e-05	0.000126	CcSEcCtD
Imatinib—Myalgia—Methotrexate—psoriasis	3.79e-05	0.000126	CcSEcCtD
Imatinib—Decreased appetite—Prednisone—psoriasis	3.78e-05	0.000125	CcSEcCtD
Imatinib—Rash—Prednisolone—psoriasis	3.77e-05	0.000125	CcSEcCtD
Imatinib—Dermatitis—Prednisolone—psoriasis	3.77e-05	0.000125	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	3.76e-05	0.000125	CcSEcCtD
Imatinib—Fatigue—Prednisone—psoriasis	3.75e-05	0.000124	CcSEcCtD
Imatinib—Headache—Prednisolone—psoriasis	3.75e-05	0.000124	CcSEcCtD
Imatinib—Discomfort—Methotrexate—psoriasis	3.75e-05	0.000124	CcSEcCtD
Imatinib—Constipation—Prednisone—psoriasis	3.72e-05	0.000123	CcSEcCtD
Imatinib—Vomiting—Hydrocortisone—psoriasis	3.72e-05	0.000123	CcSEcCtD
Imatinib—Rash—Hydrocortisone—psoriasis	3.68e-05	0.000122	CcSEcCtD
Imatinib—Dermatitis—Hydrocortisone—psoriasis	3.68e-05	0.000122	CcSEcCtD
Imatinib—Confusional state—Methotrexate—psoriasis	3.66e-05	0.000121	CcSEcCtD
Imatinib—Headache—Hydrocortisone—psoriasis	3.66e-05	0.000121	CcSEcCtD
Imatinib—Dizziness—Triamcinolone—psoriasis	3.64e-05	0.000121	CcSEcCtD
Imatinib—Anaphylactic shock—Methotrexate—psoriasis	3.63e-05	0.00012	CcSEcCtD
Imatinib—Infection—Methotrexate—psoriasis	3.61e-05	0.00012	CcSEcCtD
Imatinib—Feeling abnormal—Prednisone—psoriasis	3.58e-05	0.000119	CcSEcCtD
Imatinib—Asthenia—Dexamethasone—psoriasis	3.58e-05	0.000119	CcSEcCtD
Imatinib—Asthenia—Betamethasone—psoriasis	3.58e-05	0.000119	CcSEcCtD
Imatinib—Nervous system disorder—Methotrexate—psoriasis	3.56e-05	0.000118	CcSEcCtD
Imatinib—Thrombocytopenia—Methotrexate—psoriasis	3.56e-05	0.000118	CcSEcCtD
Imatinib—Gastrointestinal pain—Prednisone—psoriasis	3.56e-05	0.000118	CcSEcCtD
Imatinib—Nausea—Prednisolone—psoriasis	3.55e-05	0.000118	CcSEcCtD
Imatinib—Pruritus—Dexamethasone—psoriasis	3.53e-05	0.000117	CcSEcCtD
Imatinib—Pruritus—Betamethasone—psoriasis	3.53e-05	0.000117	CcSEcCtD
Imatinib—Skin disorder—Methotrexate—psoriasis	3.53e-05	0.000117	CcSEcCtD
Imatinib—Hyperhidrosis—Methotrexate—psoriasis	3.51e-05	0.000116	CcSEcCtD
Imatinib—Vomiting—Triamcinolone—psoriasis	3.5e-05	0.000116	CcSEcCtD
Imatinib—Nausea—Hydrocortisone—psoriasis	3.47e-05	0.000115	CcSEcCtD
Imatinib—Rash—Triamcinolone—psoriasis	3.47e-05	0.000115	CcSEcCtD
Imatinib—Dermatitis—Triamcinolone—psoriasis	3.47e-05	0.000115	CcSEcCtD
Imatinib—Anorexia—Methotrexate—psoriasis	3.46e-05	0.000115	CcSEcCtD
Imatinib—Urticaria—Prednisone—psoriasis	3.45e-05	0.000114	CcSEcCtD
Imatinib—Headache—Triamcinolone—psoriasis	3.45e-05	0.000114	CcSEcCtD
Imatinib—Body temperature increased—Prednisone—psoriasis	3.44e-05	0.000114	CcSEcCtD
Imatinib—Abdominal pain—Prednisone—psoriasis	3.44e-05	0.000114	CcSEcCtD
Imatinib—Diarrhoea—Dexamethasone—psoriasis	3.42e-05	0.000113	CcSEcCtD
Imatinib—Diarrhoea—Betamethasone—psoriasis	3.42e-05	0.000113	CcSEcCtD
Imatinib—Hypotension—Methotrexate—psoriasis	3.4e-05	0.000112	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Methotrexate—psoriasis	3.31e-05	0.00011	CcSEcCtD
Imatinib—Dizziness—Dexamethasone—psoriasis	3.3e-05	0.000109	CcSEcCtD
Imatinib—Dizziness—Betamethasone—psoriasis	3.3e-05	0.000109	CcSEcCtD
Imatinib—Insomnia—Methotrexate—psoriasis	3.29e-05	0.000109	CcSEcCtD
Imatinib—Nausea—Triamcinolone—psoriasis	3.27e-05	0.000108	CcSEcCtD
Imatinib—Paraesthesia—Methotrexate—psoriasis	3.26e-05	0.000108	CcSEcCtD
Imatinib—Dyspnoea—Methotrexate—psoriasis	3.24e-05	0.000107	CcSEcCtD
Imatinib—Somnolence—Methotrexate—psoriasis	3.23e-05	0.000107	CcSEcCtD
Imatinib—Hypersensitivity—Prednisone—psoriasis	3.2e-05	0.000106	CcSEcCtD
Imatinib—Dyspepsia—Methotrexate—psoriasis	3.2e-05	0.000106	CcSEcCtD
Imatinib—Vomiting—Betamethasone—psoriasis	3.17e-05	0.000105	CcSEcCtD
Imatinib—Vomiting—Dexamethasone—psoriasis	3.17e-05	0.000105	CcSEcCtD
Imatinib—Decreased appetite—Methotrexate—psoriasis	3.16e-05	0.000105	CcSEcCtD
Imatinib—Rash—Betamethasone—psoriasis	3.15e-05	0.000104	CcSEcCtD
Imatinib—Rash—Dexamethasone—psoriasis	3.15e-05	0.000104	CcSEcCtD
Imatinib—Dermatitis—Dexamethasone—psoriasis	3.15e-05	0.000104	CcSEcCtD
Imatinib—Dermatitis—Betamethasone—psoriasis	3.15e-05	0.000104	CcSEcCtD
Imatinib—Gastrointestinal disorder—Methotrexate—psoriasis	3.14e-05	0.000104	CcSEcCtD
Imatinib—Fatigue—Methotrexate—psoriasis	3.13e-05	0.000104	CcSEcCtD
Imatinib—Headache—Dexamethasone—psoriasis	3.13e-05	0.000104	CcSEcCtD
Imatinib—Headache—Betamethasone—psoriasis	3.13e-05	0.000104	CcSEcCtD
Imatinib—Asthenia—Prednisone—psoriasis	3.12e-05	0.000103	CcSEcCtD
Imatinib—Pain—Methotrexate—psoriasis	3.11e-05	0.000103	CcSEcCtD
Imatinib—Pruritus—Prednisone—psoriasis	3.08e-05	0.000102	CcSEcCtD
Imatinib—Feeling abnormal—Methotrexate—psoriasis	2.99e-05	9.92e-05	CcSEcCtD
Imatinib—Diarrhoea—Prednisone—psoriasis	2.97e-05	9.86e-05	CcSEcCtD
Imatinib—Gastrointestinal pain—Methotrexate—psoriasis	2.97e-05	9.84e-05	CcSEcCtD
Imatinib—Nausea—Betamethasone—psoriasis	2.97e-05	9.82e-05	CcSEcCtD
Imatinib—Nausea—Dexamethasone—psoriasis	2.97e-05	9.82e-05	CcSEcCtD
Imatinib—Urticaria—Methotrexate—psoriasis	2.89e-05	9.56e-05	CcSEcCtD
Imatinib—Dizziness—Prednisone—psoriasis	2.88e-05	9.53e-05	CcSEcCtD
Imatinib—Body temperature increased—Methotrexate—psoriasis	2.87e-05	9.52e-05	CcSEcCtD
Imatinib—Abdominal pain—Methotrexate—psoriasis	2.87e-05	9.52e-05	CcSEcCtD
Imatinib—Vomiting—Prednisone—psoriasis	2.76e-05	9.16e-05	CcSEcCtD
Imatinib—Rash—Prednisone—psoriasis	2.74e-05	9.08e-05	CcSEcCtD
Imatinib—Dermatitis—Prednisone—psoriasis	2.74e-05	9.07e-05	CcSEcCtD
Imatinib—Headache—Prednisone—psoriasis	2.72e-05	9.02e-05	CcSEcCtD
Imatinib—Hypersensitivity—Methotrexate—psoriasis	2.68e-05	8.87e-05	CcSEcCtD
Imatinib—Asthenia—Methotrexate—psoriasis	2.61e-05	8.64e-05	CcSEcCtD
Imatinib—Nausea—Prednisone—psoriasis	2.58e-05	8.56e-05	CcSEcCtD
Imatinib—Pruritus—Methotrexate—psoriasis	2.57e-05	8.52e-05	CcSEcCtD
Imatinib—Diarrhoea—Methotrexate—psoriasis	2.49e-05	8.24e-05	CcSEcCtD
Imatinib—Dizziness—Methotrexate—psoriasis	2.4e-05	7.96e-05	CcSEcCtD
Imatinib—Vomiting—Methotrexate—psoriasis	2.31e-05	7.65e-05	CcSEcCtD
Imatinib—Rash—Methotrexate—psoriasis	2.29e-05	7.59e-05	CcSEcCtD
Imatinib—Dermatitis—Methotrexate—psoriasis	2.29e-05	7.58e-05	CcSEcCtD
Imatinib—Headache—Methotrexate—psoriasis	2.28e-05	7.54e-05	CcSEcCtD
Imatinib—Nausea—Methotrexate—psoriasis	2.16e-05	7.15e-05	CcSEcCtD
Imatinib—ABL1—Innate Immune System—CD4—psoriasis	1.7e-05	0.000168	CbGpPWpGaD
Imatinib—KIT—Adaptive Immune System—NFKB1—psoriasis	1.69e-05	0.000168	CbGpPWpGaD
Imatinib—KIT—Immune System—HLA-DRB1—psoriasis	1.69e-05	0.000167	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—CD4—psoriasis	1.68e-05	0.000166	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—CRP—psoriasis	1.67e-05	0.000165	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—NFKB1—psoriasis	1.67e-05	0.000165	CbGpPWpGaD
Imatinib—PTGS1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.66e-05	0.000165	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—NFKB1—psoriasis	1.66e-05	0.000164	CbGpPWpGaD
Imatinib—ABL1—Immune System—HLA-B—psoriasis	1.66e-05	0.000164	CbGpPWpGaD
Imatinib—PDGFRB—Signaling by NGF—IL6—psoriasis	1.65e-05	0.000164	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CYP2S1—psoriasis	1.64e-05	0.000162	CbGpPWpGaD
Imatinib—KIT—Immune System—ICAM1—psoriasis	1.62e-05	0.000161	CbGpPWpGaD
Imatinib—PDGFRA—Disease—HLA-A—psoriasis	1.62e-05	0.00016	CbGpPWpGaD
Imatinib—KIT—Immune System—NFKBIA—psoriasis	1.61e-05	0.000159	CbGpPWpGaD
Imatinib—PDGFRA—Adaptive Immune System—NFKB1—psoriasis	1.6e-05	0.000159	CbGpPWpGaD
Imatinib—LCK—Immune System—SOCS1—psoriasis	1.6e-05	0.000159	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—HLA-DRB1—psoriasis	1.6e-05	0.000158	CbGpPWpGaD
Imatinib—KIT—Disease—APOE—psoriasis	1.59e-05	0.000158	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.59e-05	0.000157	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—HLA-A—psoriasis	1.58e-05	0.000156	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—JUN—psoriasis	1.56e-05	0.000155	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—TYK2—psoriasis	1.55e-05	0.000153	CbGpPWpGaD
Imatinib—ABL1—Immune System—HLA-A—psoriasis	1.54e-05	0.000152	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—ICAM1—psoriasis	1.54e-05	0.000152	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.53e-05	0.000151	CbGpPWpGaD
Imatinib—CA9—Metabolism—PPARG—psoriasis	1.53e-05	0.000151	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—LEP—psoriasis	1.52e-05	0.000151	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—APOE—psoriasis	1.52e-05	0.000151	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—NFKBIA—psoriasis	1.52e-05	0.000151	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—JUN—psoriasis	1.52e-05	0.000151	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—SOCS1—psoriasis	1.51e-05	0.00015	CbGpPWpGaD
Imatinib—PDGFRA—Disease—APOE—psoriasis	1.51e-05	0.000149	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—VEGFA—psoriasis	1.51e-05	0.000149	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—CRP—psoriasis	1.5e-05	0.000149	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—NFKB1—psoriasis	1.5e-05	0.000149	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—STAT3—psoriasis	1.49e-05	0.000148	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—NDUFA5—psoriasis	1.49e-05	0.000147	CbGpPWpGaD
Imatinib—KIT—Disease—NOS2—psoriasis	1.49e-05	0.000147	CbGpPWpGaD
Imatinib—ABL1—Hemostasis—VEGFA—psoriasis	1.48e-05	0.000146	CbGpPWpGaD
Imatinib—ABL1—Immune System—CRP—psoriasis	1.47e-05	0.000145	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—NFKB1—psoriasis	1.47e-05	0.000145	CbGpPWpGaD
Imatinib—ABL1—Axon guidance—IL6—psoriasis	1.46e-05	0.000144	CbGpPWpGaD
Imatinib—PDGFRB—Disease—HLA-A—psoriasis	1.46e-05	0.000144	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—NFKB1—psoriasis	1.44e-05	0.000143	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—HLA-DRB1—psoriasis	1.44e-05	0.000143	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—SOCS1—psoriasis	1.43e-05	0.000142	CbGpPWpGaD
Imatinib—LCK—Immune System—CD8A—psoriasis	1.42e-05	0.000141	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—NFKBIA—psoriasis	1.42e-05	0.000141	CbGpPWpGaD
Imatinib—ALB—Platelet activation, signaling and aggregation—VEGFA—psoriasis	1.41e-05	0.00014	CbGpPWpGaD
Imatinib—PDGFRA—Disease—NOS2—psoriasis	1.41e-05	0.000139	CbGpPWpGaD
Imatinib—ABL1—Immune System—HLA-DRB1—psoriasis	1.4e-05	0.000139	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—CD4—psoriasis	1.4e-05	0.000139	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.39e-05	0.000137	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—ICAM1—psoriasis	1.38e-05	0.000137	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—NFKBIA—psoriasis	1.37e-05	0.000136	CbGpPWpGaD
Imatinib—LCK—Immune System—HLA-B—psoriasis	1.37e-05	0.000135	CbGpPWpGaD
Imatinib—PDGFRB—Disease—APOE—psoriasis	1.36e-05	0.000135	CbGpPWpGaD
Imatinib—LCK—Cytokine Signaling in Immune system—IL6—psoriasis	1.35e-05	0.000134	CbGpPWpGaD
Imatinib—ABL1—Immune System—ICAM1—psoriasis	1.35e-05	0.000133	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—CD4—psoriasis	1.35e-05	0.000133	CbGpPWpGaD
Imatinib—ABL1—Immune System—NFKBIA—psoriasis	1.34e-05	0.000132	CbGpPWpGaD
Imatinib—LCK—Signaling by NGF—IL6—psoriasis	1.33e-05	0.000131	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—CARM1—psoriasis	1.33e-05	0.000131	CbGpPWpGaD
Imatinib—KIT—Immune System—TYK2—psoriasis	1.32e-05	0.00013	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—TNF—psoriasis	1.29e-05	0.000128	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—SOCS1—psoriasis	1.29e-05	0.000128	CbGpPWpGaD
Imatinib—PDGFRB—Disease—NOS2—psoriasis	1.27e-05	0.000125	CbGpPWpGaD
Imatinib—LCK—Immune System—HLA-A—psoriasis	1.27e-05	0.000125	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CYP2S1—psoriasis	1.26e-05	0.000125	CbGpPWpGaD
Imatinib—ALB—Hemostasis—NOS2—psoriasis	1.26e-05	0.000124	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—JUN—psoriasis	1.25e-05	0.000124	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—TYK2—psoriasis	1.25e-05	0.000123	CbGpPWpGaD
Imatinib—KIT—Immune System—IFNG—psoriasis	1.23e-05	0.000122	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.23e-05	0.000121	CbGpPWpGaD
Imatinib—KIT—Disease—TYK2—psoriasis	1.22e-05	0.00012	CbGpPWpGaD
Imatinib—LCK—Hemostasis—VEGFA—psoriasis	1.22e-05	0.00012	CbGpPWpGaD
Imatinib—LCK—Immune System—CRP—psoriasis	1.21e-05	0.00012	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—NFKB1—psoriasis	1.21e-05	0.000119	CbGpPWpGaD
Imatinib—KIT—Immune System—CD4—psoriasis	1.19e-05	0.000118	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.19e-05	0.000118	CbGpPWpGaD
Imatinib—LCK—Disease—HLA-A—psoriasis	1.17e-05	0.000116	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—IFNG—psoriasis	1.17e-05	0.000116	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—TYK2—psoriasis	1.16e-05	0.000115	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—NFKB1—psoriasis	1.16e-05	0.000115	CbGpPWpGaD
Imatinib—LCK—Immune System—HLA-DRB1—psoriasis	1.16e-05	0.000114	CbGpPWpGaD
Imatinib—PDGFRA—Disease—TYK2—psoriasis	1.15e-05	0.000114	CbGpPWpGaD
Imatinib—ALB—Metabolism—CARM1—psoriasis	1.14e-05	0.000113	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—CAT—psoriasis	1.14e-05	0.000113	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—CAT—psoriasis	1.13e-05	0.000112	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—CD4—psoriasis	1.13e-05	0.000112	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—CAT—psoriasis	1.13e-05	0.000112	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—TYK2—psoriasis	1.12e-05	0.000111	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—LEP—psoriasis	1.12e-05	0.000111	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—APOE—psoriasis	1.12e-05	0.000111	CbGpPWpGaD
Imatinib—ABL1—Hemostasis—TP53—psoriasis	1.12e-05	0.00011	CbGpPWpGaD
Imatinib—LCK—Immune System—ICAM1—psoriasis	1.11e-05	0.00011	CbGpPWpGaD
Imatinib—KIT—Innate Immune System—IL6—psoriasis	1.11e-05	0.00011	CbGpPWpGaD
Imatinib—LCK—Immune System—NFKBIA—psoriasis	1.1e-05	0.000109	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.1e-05	0.000109	CbGpPWpGaD
Imatinib—KIT—Disease—CD4—psoriasis	1.1e-05	0.000109	CbGpPWpGaD
Imatinib—ABL1—Immune System—TYK2—psoriasis	1.1e-05	0.000108	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—CAT—psoriasis	1.09e-05	0.000108	CbGpPWpGaD
Imatinib—LCK—Disease—APOE—psoriasis	1.09e-05	0.000108	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.07e-05	0.000106	CbGpPWpGaD
Imatinib—KIT—Immune System—JUN—psoriasis	1.07e-05	0.000106	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—LEP—psoriasis	1.06e-05	0.000105	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—APOE—psoriasis	1.06e-05	0.000105	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—IFNG—psoriasis	1.05e-05	0.000104	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—CAT—psoriasis	1.05e-05	0.000104	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.05e-05	0.000104	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—IL6—psoriasis	1.05e-05	0.000104	CbGpPWpGaD
Imatinib—PDGFRA—Disease—CD4—psoriasis	1.04e-05	0.000103	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—IL6—psoriasis	1.04e-05	0.000103	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—NFKBIA—psoriasis	1.04e-05	0.000103	CbGpPWpGaD
Imatinib—PDGFRB—Disease—TYK2—psoriasis	1.04e-05	0.000103	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—SOCS1—psoriasis	1.04e-05	0.000102	CbGpPWpGaD
Imatinib—KIT—Immune System—NFKB1—psoriasis	1.03e-05	0.000102	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—CARM1—psoriasis	1.03e-05	0.000102	CbGpPWpGaD
Imatinib—ABL1—Immune System—IFNG—psoriasis	1.03e-05	0.000102	CbGpPWpGaD
Imatinib—LCK—Disease—NOS2—psoriasis	1.02e-05	0.000101	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—CD4—psoriasis	1.02e-05	0.000101	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—CXCL8—psoriasis	1.01e-05	0.0001	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—JUN—psoriasis	1.01e-05	0.0001	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1e-05	9.94e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—CARM1—psoriasis	1e-05	9.91e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—CD4—psoriasis	9.91e-06	9.8e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—NFKBIA—psoriasis	9.85e-06	9.75e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—NFKB1—psoriasis	9.72e-06	9.62e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	9.59e-06	9.49e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—LEP—psoriasis	9.52e-06	9.42e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—APOE—psoriasis	9.52e-06	9.42e-05	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—IL6—psoriasis	9.44e-06	9.34e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—CARM1—psoriasis	9.44e-06	9.34e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—JUN—psoriasis	9.41e-06	9.32e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—CD4—psoriasis	9.39e-06	9.29e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—CARM1—psoriasis	9.36e-06	9.26e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—STAT3—psoriasis	9.23e-06	9.13e-05	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—IL6—psoriasis	9.2e-06	9.1e-05	CbGpPWpGaD
Imatinib—LCK—Hemostasis—TP53—psoriasis	9.19e-06	9.1e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—JUN—psoriasis	9.1e-06	9e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—NFKB1—psoriasis	9.06e-06	8.97e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—TYK2—psoriasis	9.02e-06	8.93e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—NFKBIA—psoriasis	8.87e-06	8.78e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—JUN—psoriasis	8.87e-06	8.78e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—APOE—psoriasis	8.85e-06	8.76e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—APOE—psoriasis	8.78e-06	8.68e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—APOE—psoriasis	8.76e-06	8.67e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—NFKB1—psoriasis	8.76e-06	8.67e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	8.75e-06	8.66e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—STAT3—psoriasis	8.74e-06	8.65e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	8.58e-06	8.49e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—NFKB1—psoriasis	8.54e-06	8.45e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—TYK2—psoriasis	8.52e-06	8.43e-05	CbGpPWpGaD
Imatinib—KIT—Disease—STAT3—psoriasis	8.52e-06	8.43e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—APOE—psoriasis	8.51e-06	8.42e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—IFNG—psoriasis	8.45e-06	8.36e-05	CbGpPWpGaD
Imatinib—LCK—Disease—TYK2—psoriasis	8.33e-06	8.24e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—VEGFA—psoriasis	8.23e-06	8.14e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—APOE—psoriasis	8.17e-06	8.08e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—CAT—psoriasis	8.16e-06	8.08e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—CD4—psoriasis	8.16e-06	8.07e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—STAT3—psoriasis	8.14e-06	8.06e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—TYK2—psoriasis	8.07e-06	7.98e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—STAT3—psoriasis	8.07e-06	7.98e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CARM1—psoriasis	8e-06	7.91e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—STAT3—psoriasis	7.87e-06	7.79e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—PPARG—psoriasis	7.71e-06	7.63e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—STAT3—psoriasis	7.67e-06	7.59e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—PPARG—psoriasis	7.64e-06	7.56e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—APOE—psoriasis	7.64e-06	7.56e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—LEP—psoriasis	7.64e-06	7.56e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—PPARG—psoriasis	7.63e-06	7.55e-05	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—IL6—psoriasis	7.58e-06	7.5e-05	CbGpPWpGaD
Imatinib—LCK—Disease—CD4—psoriasis	7.53e-06	7.45e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.47e-06	7.4e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—CXCL8—psoriasis	7.42e-06	7.34e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—PPARG—psoriasis	7.41e-06	7.33e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—JUN—psoriasis	7.3e-06	7.23e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—VEGFA—psoriasis	7.27e-06	7.2e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—TYK2—psoriasis	7.27e-06	7.19e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—STAT3—psoriasis	7.27e-06	7.19e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—NFKBIA—psoriasis	7.12e-06	7.05e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PPARG—psoriasis	7.11e-06	7.04e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—CAT—psoriasis	7.03e-06	6.96e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—NFKB1—psoriasis	7.03e-06	6.96e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CXCL8—psoriasis	7.02e-06	6.95e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—JUN—psoriasis	6.9e-06	6.83e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—NFKB1—psoriasis	6.64e-06	6.57e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—JUN—psoriasis	6.53e-06	6.46e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—IL6—psoriasis	6.45e-06	6.38e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—APOE—psoriasis	6.34e-06	6.28e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CXCL8—psoriasis	6.33e-06	6.26e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—STAT3—psoriasis	6.32e-06	6.25e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—CAT—psoriasis	6.31e-06	6.25e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—NFKB1—psoriasis	6.29e-06	6.22e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—TP53—psoriasis	6.21e-06	6.15e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CARM1—psoriasis	6.17e-06	6.11e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—CAT—psoriasis	6.16e-06	6.1e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—IL6—psoriasis	6.1e-06	6.04e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—VEGFA—psoriasis	6.03e-06	5.96e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—STAT3—psoriasis	5.97e-06	5.91e-05	CbGpPWpGaD
Imatinib—KIT—Disease—IL6—psoriasis	5.95e-06	5.89e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—JUN—psoriasis	5.88e-06	5.82e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TYK2—psoriasis	5.83e-06	5.77e-05	CbGpPWpGaD
Imatinib—LCK—Disease—STAT3—psoriasis	5.83e-06	5.77e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—CAT—psoriasis	5.81e-06	5.75e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—CAT—psoriasis	5.75e-06	5.7e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—VEGFA—psoriasis	5.7e-06	5.65e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—IL6—psoriasis	5.69e-06	5.63e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—NFKB1—psoriasis	5.66e-06	5.6e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—STAT3—psoriasis	5.65e-06	5.59e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—IL6—psoriasis	5.63e-06	5.58e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PPARG—psoriasis	5.53e-06	5.47e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—IL6—psoriasis	5.5e-06	5.44e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—TP53—psoriasis	5.49e-06	5.44e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—APOE—psoriasis	5.46e-06	5.41e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—IL6—psoriasis	5.36e-06	5.3e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—VEGFA—psoriasis	5.14e-06	5.09e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—STAT3—psoriasis	5.09e-06	5.04e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CXCL8—psoriasis	5.08e-06	5.03e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—IL6—psoriasis	5.08e-06	5.02e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CAT—psoriasis	4.92e-06	4.87e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—APOE—psoriasis	4.9e-06	4.85e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—APOE—psoriasis	4.79e-06	4.74e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PPARG—psoriasis	4.76e-06	4.71e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—JUN—psoriasis	4.72e-06	4.67e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—TP53—psoriasis	4.55e-06	4.51e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—NFKB1—psoriasis	4.54e-06	4.5e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—APOE—psoriasis	4.51e-06	4.46e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—APOE—psoriasis	4.47e-06	4.43e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—IL6—psoriasis	4.41e-06	4.37e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—TP53—psoriasis	4.31e-06	4.27e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PPARG—psoriasis	4.27e-06	4.23e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PPARG—psoriasis	4.17e-06	4.13e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—IL6—psoriasis	4.17e-06	4.13e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—VEGFA—psoriasis	4.12e-06	4.08e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—STAT3—psoriasis	4.08e-06	4.04e-05	CbGpPWpGaD
Imatinib—LCK—Disease—IL6—psoriasis	4.07e-06	4.03e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—IL6—psoriasis	3.95e-06	3.9e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PPARG—psoriasis	3.93e-06	3.89e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PPARG—psoriasis	3.89e-06	3.85e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—TP53—psoriasis	3.88e-06	3.84e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—APOE—psoriasis	3.82e-06	3.78e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CAT—psoriasis	3.8e-06	3.76e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—IL6—psoriasis	3.55e-06	3.52e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PPARG—psoriasis	3.33e-06	3.29e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TP53—psoriasis	3.12e-06	3.08e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—APOE—psoriasis	2.95e-06	2.92e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IL6—psoriasis	2.85e-06	2.82e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PPARG—psoriasis	2.57e-06	2.54e-05	CbGpPWpGaD
